Results 31 to 40 of about 3,776 (143)

Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis [PDF]

, 2022
Single-agent Talimogene Laherparepvec (T-VEC) was developed for treatment of unresectable and injectable stage III-IV melanoma. Since its approval and reimbursement, studies have reported varying response rates.
van Houdt, Winan J., van de Wiel, Bart A., Mulder, Evalyn E. A. P., Klop, Willem M. C., van der Hiel, Bernies, Grunhagen, Dirk J.; id_orcid, Stahlie, Emma H.A., van Akkooi, Alexander C. J., Stahlie, Emma H. A., Wouters, Michel W. J. M., Schrage, Yvonne M., Zuur, Charlotte L., Klop, Willem M.C., Reijers, Sophie, Balduzzi, Sara, Mulder, Evalyn E.A.P., Grunhagen, Dirk J., van Akkooi, Alexander C.J., Wouters, Michel W.J.M.   +18 more
core   +3 more sources

Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis

Virology Journal, 2021
Background Oncolytic viruses (OVs) have shown prospects in advanced and metastatic cancer, and many clinical trials have been carried out. To compare OV therapies comprehensively and provide a categorized profile and ranking of efficacy and safety, a ...
Ruiyang Xie, Xingang Bi, Bingqing Shang, Aiping Zhou, Hongzhe Shi, Jianzhong Shou   +5 more
doaj   +1 more source

The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond. [PDF]

Cells
Oncolytic viruses represent an emerging class of therapeutic agents that have the potential to transform the care of patients with melanoma. In this narrative review, we describe the evolution of oncolytic virus approaches.
Smestad J, Rieth J, Laux D, Milhem M.
europepmc   +2 more sources

A practical guide to the handling and administration of talimogene laherparepvec in Europe [PDF]

, 2017
Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe.
Michielin, O, Dummer, R, Michielin, O., Malvehy, J., Pezzani Grüter, I., Michielin, Olivier, Malvehy, Josep, Josep Malvehy, Frauchiger, Anna Lisa, Grove, L, Kevin Harrington, Frauchiger, AL, Lorna Grove, Grove, L., Pezzani Grüter, I, Reinhard Dummer, Anna Lisa Frauchiger, Harrington, K.J., Harrington, KJ, Harrington, Kevin J, Frauchiger, A.L., Isabella Pezzani Grüter, Dummer, R., Dummer, Reinhard, Malvehy, J, Olivier Michielin, Grove, Lorna   +26 more
core   +1 more source

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

, 2018
Talimogene laherparepvec is a genetically modified herpes simplex virus-1-based oncolytic immunotherapy for the local treatment of unresectable cutaneous, subcutaneous, and nodal tumors in patients with melanoma recurrence following surgery.
Jose Lutzky, Jason Chesney, Batty, Nicolas, Russell E. Brown, Gerald F. Downey, Amatruda, Thomas, Nicolas Batty, Downey, Gerald F, Gerald Linette, Nemunaitis, John, Sanjay Awasthi, Triozzi, Pierre, Windham, Christopher, Pierre Triozzi, Lutzky, Jose, Hutchins, Laura, Downey, Gerald F., Brendan Curti, Linette, Gerald, John Nemunaitis, Brown, Russell E, Thomas Amatruda, Eric Whitman, Tan, Marcus C B, Brown, Russell E., Awasthi, Sanjay, Christopher Windham, Curti, Brendan, Laura Hutchins, Chesney, Jason, Whitman, Eric, Tan, Marcus C. B., Marcus C.B. Tan   +32 more
core   +2 more sources

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

OncoImmunology, 2019
In a recent edition of Science Translational Medicine, we identified an enhanced therapeutic activity when talimogene laherparepvec (T-VEC) was combined with MEK inhibition in murine melanoma tumor models.
Praveen K. Bommareddy, Samuel D. Rabkin, Howard L. Kaufman   +2 more
doaj   +1 more source

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases. [PDF]

ESMO Open, 2023
BACKGROUND Talimogene laherparepvec (T-VEC), a first-in-class oncolytic viral immunotherapy, enhances tumor-specific immune activation. T-VEC combined with atezolizumab, which blocks inhibitor T-cell checkpoints, could provide greater benefit than ...
Hecht JR, Raman SS, Chan A, Kalinsky K, Baurain JF, Jimenez MM, Garcia MM, Berger MD, Lauer UM, Khattak A, Carrato A, Zhang Y, Liu K, Cha E, Keegan A, Bhatta S, Strassburg CP, Roohullah A.   +17 more
europepmc   +3 more sources

Complete response of Merkel cell carcinoma with talimogene laherparepvec (TVEC) monotherapy [PDF]

, 2022
Merkel cell carcinoma (MCC) is a rare neuroendocrine neoplasm, warranting surgical excision with sentinel lymph node biopsy. In later stages, adjuvant chemotherapy and radiation are required owing to its aggressive malignant behavior.
Tchanque-Fossuo, Catherine, Durkin, John, Stepenaskie, Shelly, Casale, Fiore   +3 more
core   +1 more source

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC). [PDF]

J Surg Oncol, 2021
Talimogene laherparepvec (T-VEC) is a genetically modified herpes simplex virus-1-based oncolytic immunotherapy and has been approved for the local treatment of unresectable (stage IIIB/C and IVM1a) cutaneous melanoma.
Mulder EEAP, Stahlie EHA, Verver D, Lemstra C, Been LB, Mooyaart AL, Brabander T, Vegt E, Verburg FA, van der Veldt AAM, Verhoef C, van Akkooi ACJ, Grünhagen DJ.   +12 more
europepmc   +3 more sources

Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2. [PDF]

Ther Adv Med Oncol
Background: Talimogene laherparepvec (T-VEC) and interleukin-2 (IL-2) are both used in the intralesional treatment of melanoma skin metastases. T-VEC received regulatory approval from the European Medicines Agency and the U.S.
Reitmajer M, Nanz L, Müller N, Leiter U, Amaral T, Aebischer V, Flatz L, Forschner A.   +7 more
europepmc   +2 more sources